RecruitingNot ApplicableNCT07122713

Definitive Radiation Therapy for Inoperable Breast Cancer

Multi-institutional Prospective Pilot Study of Definitive Breast Radiation Therapy for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery


Sponsor

Alexander Stessin

Enrollment

30 participants

Start Date

Dec 8, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to find out if adding radiation therapy to routine medications for breast cancer helps in reducing and preventing the cancer from getting worse. Patients with a locally advanced breast cancer who cannot, or do not want to, undergo surgery are eligible to participate. Participation in this study does not prevent you from undergoing surgery in the future.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria5

  • Biopsy proven invasive carcinoma of the breast, either lobular, ductal and/or no special type
  • T1-T4, N0-2, M0-1 invasive breast carcinoma by radiological or clinical criteria
  • Cancer is deemed unresectable, or the patient is a poor surgical candidate as determined following evaluation by a surgeon, or patient declines surgery.
  • Life expectancy \> 6 months
  • Negative pregnancy test at the time of start of treatment in any female of reproductive age

Exclusion Criteria3

  • Concurrent systemic therapy (except for endocrine therapy, HER2-targeted therapy, or immunotherapy which are permitted)
  • Prior radiation to ipsilateral breast or regional nodes
  • Inability to receive study treatment planning and treatment secondary to body habitus

Interventions

RADIATIONWhole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor

Radiation with 26Gy to the whole breast and 40Gy simultaneous integrated boost to gross disease in the breast, in five fractions

RADIATIONWhole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes

Radiation with 26Gy to the whole breast and regional nodes with a 40Gy simultaneous integrated boost to gross disease in breast and ipsilateral axillary nodal areas, in five fractions


Locations(1)

Stony Brook University Cancer Center

Stony Brook, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07122713


Related Trials